Log In Sign up
The largest database of trusted experimental protocols

Qiaseq human breast cancer panel

Manufactured by Qiagen
Visit Supplier

The QIAseq Human Breast Cancer Panel is a targeted gene panel designed for the analysis of somatic mutations in breast cancer samples. The panel covers the coding regions of 76 genes associated with breast cancer. It enables the identification of genetic variants that may be relevant for disease diagnosis, prognosis, and treatment selection.

Automatically generated - may contain errors

Lab products found in correlation

Qiaseq library quant assay kit, by Qiagen (5 mentions) Generead human comprehensive cancer panel, by Qiagen (5 mentions) Miseq sequencer, by Illumina (5 mentions)

Spelling variants of this product

QIAseq Human Breast Cancer Panel (DHS-001Z, (2 citations)

5 protocols using qiaseq human breast cancer panel

1

Comprehensive Breast Cancer Gene Panel Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The QIAseq Human Breast Cancer Panel (93 genes, DHS-001Z; Qiagen) and the GeneRead Human Comprehensive Cancer Panel (160 genes, NGHS-501X; Qiagen) were used for library construction according to the manufacturer’s instructions. The libraries were assessed using a QIAseq Library Quant Assay Kit (#QSTF-ILZ-R; Qiagen) and applied to a MiSeq sequencer (Illumina, San Diego, CA, USA). The Qiagen web portal (https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/) was utilized for data analysis [16 (link)]. For alignment, GenomeBrowse (http://goldenhelix.com/products/GenomeBrowse/index.html) was used, and GRCH37 was used as the human genome reference. A commercial bioinformatic analysis service (Mitsubishi Space Software Co. Ltd., Tokyo, Japan) was asked to interpret the GeneRead Human Comprehensive Cancer Panel results. CNV was calculated using the cloud analysis pipeline of the Qiagen web portal, and corrected for the percent tumor content. Four or more and one or fewer CNVs were regarded as significant.
Akahane T., Kanomata N., Harada O., Yamashita T., Kurebayashi J., Tanimoto A, & Moriya T. (2020). Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions. BMC Cancer, 20, 944.
+ Open protocol
+ Expand
2

Comprehensive Breast Cancer Mutation Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
The QIAseq Human Breast Cancer Panel (93 genes, DHS-001Z; Qiagen) and the GeneRead Human Comprehensive Cancer Panel (160 genes, NGHS-501X; Qiagen) were used for library construction according to the manufacturer's instructions. The libraries were assessed using a QIAseq Library Quant Assay Kit (#QSTF-ILZ-R; Qiagen) and applied to a MiSeq sequencer (Illumina, San Diego, CA, USA). The Qiagen web portal (https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/) was utilized for data analysis [16] . For alignment, GenomeBrowse (http://goldenhelix.com/products/GenomeBrowse/index.html) was used, and GRCH37 was used as the human genome reference. A commercial bioinformatic analysis service (Mitsubishi Space Software Co. Ltd, Tokyo, Japan) was asked to interpret the GeneRead Human Comprehensive Cancer Panel results. CNV was calculated using the cloud analysis pipeline of the Qiagen web portal, and corrected for the percent tumor content. Four or more and one or fewer CNVs were regarded as signi cant.
Akahane T., Kanomata N., Harada O., Yamashita T., Kurebayashi J., Tanimoto A., & Moriya T. (2020). Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
+ Open protocol
+ Expand
3

Comprehensive Breast Cancer Mutation Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
The QIAseq Human Breast Cancer Panel (93 genes, DHS-001Z; Qiagen) and the GeneRead Human Comprehensive Cancer Panel (160 genes, NGHS-501X; Qiagen) were used for library construction according to the manufacturer's instructions. The libraries were assessed using a QIAseq Library Quant Assay Kit (#QSTF-ILZ-R; Qiagen) and applied to a MiSeq sequencer (Illumina, San Diego, CA, USA). The Qiagen web portal (https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/) was utilized for data analysis [16] . For alignment, GenomeBrowse (http://goldenhelix.com/products/GenomeBrowse/index.html) was used, and GRCH37 was used as the human genome reference. A commercial bioinformatic analysis service (Mitsubishi Space Software Co. Ltd, Tokyo, Japan) was asked to interpret the GeneRead Human Comprehensive Cancer Panel results. CNV was calculated using the cloud analysis pipeline of the Qiagen web portal, and corrected for the percent tumor content. Four or more and one or fewer CNVs were regarded as signi cant.
Akahane T., Kanomata N., Harada O., Yamashita T., Kurebayashi J., Tanimoto A., & Moriya T. (2020). Targeted next generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
+ Open protocol
+ Expand
4

Breast Cancer Panel and Comprehensive Cancer Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
The QIAseq Human Breast Cancer Panel (93 genes, DHS-001Z; Qiagen) and the GeneRead Human Comprehensive Cancer Panel (160 genes, NGHS-501X; Qiagen) were used for library construction according to the manufacturer's instructions. The libraries were assessed using a QIAseq Library Quant Assay Kit (#QSTF-ILZ-R; Qiagen) and applied to a MiSeq sequencer (Illumina, San Diego, CA, USA). The Qiagen web portal (https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/) was utilized for data analysis [16] . For alignment, GenomeBrowse (http://goldenhelix.com/products/GenomeBrowse/index.html) was used, and GRCH37 was used as the human genome reference. A commercial bioinformatic analysis service (Mitsubishi Space Software Co. Ltd, Tokyo, Japan) was asked to interpret the GeneRead Human Comprehensive Cancer Panel results. CNV was calculated using the cloud analysis pipeline of the Qiagen web portal, and corrected for the percent tumor content. Four or more and one or fewer CNVs were regarded as significant.
Akahane T., Kanomata N., Harada O., Yamashita T., Kurebayashi J., Tanimoto A., & Moriya T. (2020). Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
+ Open protocol
+ Expand
5

Comprehensive Breast Cancer Mutation Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
The QIAseq Human Breast Cancer Panel (93 genes, DHS-001Z; Qiagen) and the GeneRead Human Comprehensive Cancer Panel (160 genes, NGHS-501X; Qiagen) were used for library construction according to the manufacturer's instructions. The libraries were assessed using a QIAseq Library Quant Assay Kit (#QSTF-ILZ-R; Qiagen) and applied to a MiSeq sequencer (Illumina, San Diego, CA, USA). The Qiagen web portal (https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/) was utilized for data analysis [16] . For alignment, GenomeBrowse (http://goldenhelix.com/products/GenomeBrowse/index.html) was used, and GRCH37 was used as the human genome reference. A commercial bioinformatic analysis service (Mitsubishi Space Software Co. Ltd, Tokyo, Japan) was asked to interpret the GeneRead Human Comprehensive Cancer Panel results. CNV was calculated using the cloud analysis pipeline of the Qiagen web portal, and corrected for the percent tumor content. Four or more and one or fewer CNVs were regarded as signi cant.
Akahane T., Kanomata N., Harada O., Yamashita T., Kurebayashi J., Tanimoto A., & Moriya T. (2020). Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!